Empiric Calcium in Massive Transfusion
Launched by UNIVERSITY OF CALIFORNIA, IRVINE · Jul 11, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called “Empiric Calcium in Massive Transfusion,” is investigating whether giving calcium through an IV (intravenous) can help patients who have lost a lot of blood due to trauma. Calcium is important because it helps blood clot, which can stop bleeding. The researchers want to find out if giving calcium right away can reduce the need for blood transfusions, lower the use of medications that support blood pressure, and ultimately help patients survive after serious injuries.
The trial is looking for trauma patients who are receiving a massive blood transfusion. To be eligible, participants must not be pregnant, must not have certain medical conditions like high calcium levels or hemophilia, and cannot be prisoners. If someone meets these criteria and participates in the study, they can expect to receive standard care along with the calcium treatment being tested. This study is important because it could potentially improve outcomes for patients who are critically injured and losing a lot of blood.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Trauma patients receiving massive transfusion protocol
- Exclusion Criteria:
- • Pregnancy
- • Prisoners
- • Known history of hypercalcemia
- • Active hyperparathyroidism
- • Hemophilia
About University Of California, Irvine
The University of California, Irvine (UCI) is a leading research institution renowned for its commitment to advancing health and medical knowledge through innovative clinical trials. With a robust infrastructure for clinical research, UCI fosters interdisciplinary collaboration among its esteemed faculty and researchers, aiming to translate scientific discoveries into effective therapeutic solutions. The university prioritizes ethical standards and participant safety while addressing critical healthcare challenges across various fields, including cancer, neurology, and public health. UCI's dedication to excellence in research and education positions it as a pivotal contributor to the advancement of clinical science and patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Jeffry Nahmias, MD
Principal Investigator
University of California, Irvine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported